FOSUN PHARMA News

Fosun Pharmaceutical (600196): Focus on operating cash flow optimization innovation

ZhongHang SecuritiesOct 30 00:00

Fosun Pharmaceuticals (600196): 24Q3 net profit YOY +55.4% slightly better than expected

Yuanta Securities (Hong Kong)Oct 30 00:00

Fosun Group (600196): Q3 results returned year on year, growth momentum for innovative drugs increased

Galaxy SecuritiesOct 29 00:00

Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.

Zhitong FinanceOct 17 09:53

Credit Suisse: Raises the target price of fosun pharma (02196) listed in Hong Kong to 18 Hong Kong dollars, maintains a shareholding rating

Zhitong FinanceOct 16 14:55

Guolian Securities gives a "shareholding" rating to Fosun Pharma (02196), operation is improving, focusing on innovative drugs and high-value medical devices.

Zhitong FinanceAug 29 16:44

Major bank rating | Citigroup: Lowered Fosun Pharma's target price to HKD 20, and lowered revenue and EPS forecasts.

Gelonghui FinanceAug 29 15:36

Fosun Pharmaceutical (600196): The operation of pharmaceuticals, devices and medical services is improving

Aug 28 16:12

Fosun Pharmaceutical (600196): The innovative drug sector has performed well and continues to transform and upgrade

Galaxy SecuritiesAug 28 00:00

Research Report Nuggets|Citic Sec: Give Fosun Pharma a 'Buy' Rating, Profit Margin Expected to Gradually Improve.

Gelonghui FinanceJul 25 10:25

CITIC Securities maintains a "buy" rating for Fosun Pharma (600196.SH, 02196) with a target price of 32 yuan, focusing on innovation and accelerating realization of business.

Zhitong FinanceJul 24 15:50

BofA Merrill Lynch is bullish! Raised the target price of Fosun Pharma's (02196) H shares to 17 yuan, accelerating innovation and transformation to achieve results.

Zhitong FinanceJul 12 15:08

Credit Rating Report|Lyon: Reiterates Fosun Pharma's 'Outperform' rating, with a target price of HKD 14.6 per H share.

Gelonghui FinanceJun 25 15:04

Fosun Pharmaceutical (600196): Continuing to promote innovation and transformation

May 14 19:26

Fosun Pharmaceuticals (600196): The first quarter met expectations and expected marginal improvement

May 4 13:16

Research Report: Zheshang Securities: Maintaining Fosun Pharmaceuticals' “Buy” Rating, Optimistic About the Company's International Implementation

Gelonghui FinanceApr 9 17:33

Fosun Pharmaceutical (600196): Optimistic about the continued advancement of internationalization & innovation

Apr 9 15:41

Zhongtai Securities released a research report on April 8 stating that it gave Fosun Pharmaceuticals (600196.SH) a purchase rating. The main reasons for the rating include: 1) the pharmaceutical industry remains steady, and investment in innovation remain

Zhitong FinanceApr 9 10:01

Fosun Pharmaceutical (600196): The deduction of non-profits is in line with expectations, and all lines are expected to accelerate growth

Apr 3 00:00

Fosun Pharmaceutical (600196): Performance is in line with expectations, and 2024 ushered in multiple improvements

Mar 28 07:46